GlaxoSmithKline: Neoplasms trials

The registry lists 150 Neoplasms studies with GlaxoSmithKline as lead sponsor. 6 are open to participants now and 60 have results posted.

Phase 1 95Phase 2 36Phase 3 7Phase 4 2No phase 17(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) DeficiencyCompletedNCT01458067Phase 1
• A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaWithdrawnNCT01445587Phase 2
• PET Study to Study Tumour ApoptosisTerminatedNCT01428440Phase 2
• Absolute Bioavialability of GSK1120212CompletedNCT01416337Phase 1
• Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212CompletedNCT01387204Phase 1
• GSK1120212 Food-effect StudyCompletedNCT01371487Phase 1
• Role of Early Versus Late Switch to Lapatinib-CapecitabineTerminatedNCT01357863
• A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid TumorsCompletedNCT01340846Phase 1
• Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid TumorsCompletedNCT01340833Phase 1
• Economic Analyses of the REDUCE TrialCompletedNCT01337258
• Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaWithdrawnNCT01328106Phase 2
• Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast CancerCompletedNCT01290354Phase 1
• An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian CancerCompletedNCT01266954Phase 1
• An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid TumorsCompletedNCT01262963Phase 1
• Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With LapatinibCompletedNCT01248897
• Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.TerminatedNCT01248858Phase 1
• An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive TumorCompletedNCT01231568Phase 1
• Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical CancerCompletedNCT01221987
• Malignancy Meta Analysis for BRL49653CompletedNCT01195259
• Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelCompletedNCT01192165Phase 1
• A Study of PNT2258 in Patients With Advanced Solid TumorsCompletedNCT01191775Phase 1
• Safety, Pharmacokinetics (PK) of AKT and MEK CombinationCompletedNCT01138085Phase 1
• Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid TumorsCompletedNCT01138033Phase 1
• A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)TerminatedNCT01110603Phase 1
• Brain Metastasis in Breast Cancer PatientsCompletedNCT01077648
• Breast Cancer With Over-expression of erbB2-BRAINSTORMCompletedNCT01064349
• Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy VolunteersCompletedNCT00996671Phase 1
• An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell CarcinomaCompletedNCT00992121Phase 1
• Regulatory TYKERB® Tablets PMSCompletedNCT00975988
• A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer SubjectsCompletedNCT00955773Phase 1
• A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795CompletedNCT00920257Phase 1
• A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic ChemotherapyWithdrawnNCT00891761Phase 3
• A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid TumorsCompletedNCT00880321Phase 1
• VEG111485: A QTc Study of PazopanibCompletedNCT00861029Phase 1
• A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1
• A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid TumorsCompletedNCT00722293Phase 1
• The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.CompletedNCT00706199
• Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or LymphomaCompletedNCT00687622Phase 1
• Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic MalignanciesWithdrawnNCT00666081Phase 1
• Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins LymphomaCompletedNCT00536835Phase 1
• Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
• Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory CancerCompletedNCT00504790Phase 1
• A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18CompletedNCT00500058Phase 1
• Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693TerminatedNCT00493818Phase 1
• A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal FunctionCompletedNCT00483860Phase 1
• Topotecan Pharmacokinetic Characterization StudyCompletedNCT00361803Phase 1
• Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The EsophagusCompletedNCT00259987Phase 2
• Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)CompletedNCT00148902Phase 1
• Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or LymphomasCompletedNCT00085904Phase 1
• Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerCompletedNCT00061308Phase 2